Celcuity (NasdaqCM:CELC) Earnings Call Presentation

Phase 3 VIKTORIA-1 HR+/HER2-/PIK3CA WT Trial Results Gedatolisib is an investigational agent and is not approved by any regulatory agency as a treatment for any indication. October 20, 2025 Forward-Looking Statements This presentation contains statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to Celcuity's business, operations, and financial condition, and include but are not limited to our current beli ...